Do multinational corporations have an advantage in China for approval procedures?
This article was originally published in SRA
Executive Summary
Multinational corporations seeking to market innovative medicines in China are generally regarded by local companies as having an unfair advantage in relation to procedures at the China Food and Drug Administration and the agency's Center for Drug Evaluation.